Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hainan Shuangcheng Pharmaceuticals

Request full access

Specialized manufacturer of synthetic peptide API and drugs

Haikou, ChinaFounded 2000

About Hainan Shuangcheng Pharmaceuticals

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (HNSP) is a publicly-traded pharmaceutical company specializing in the research, development, manufacturing, and marketing of chemically synthesized peptide drugs. Founded on May 22, 2000, the company has established itself as a high-tech enterprise with a comprehensive technology system for peptide drug synthesis, purification, and formulation. The company's legal representative is Wang Chengdong. HNSP was listed on the Shenzhen Stock Exchange on August 8, 2012.

The company's business model is centered on the production and sale of both Active Pharmaceutical Ingredients (APIs) and finished drug products to a global market, with sales in North America, Europe, and the Middle East. It also provides Contract Development and Manufacturing Organization (CDMO) services. The firm's product portfolio includes treatments for liver disease, cancer, and infectious diseases. Key products include Thymalfasin for injection (brand name "Jitai") for immune enhancement, Somatostatin for injection, and Bivalirudin for injection, which has received FDA approval. Several of its products and facilities are approved by international regulatory bodies, including the U.S. FDA and the Italian Medicines Agency (AIFA).

Headquartered in Haikou, Hainan Province, China, the company operates R&D and manufacturing facilities at its Haikou site and is expanding with new facilities in Ningbo. It also has a subsidiary in Italy, reflecting its strategy to become a leading global supplier of peptide APIs and a major producer of generic peptide drug formulations. The company's distribution network covers over 30 provinces in China, with more than 600 partner medical businesses and product coverage in over 10,000 hospitals.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2012
Outcome tier
Colt$25–100M revenue

Hainan Shuangcheng Pharmaceuticals in the Haikou ecosystem

Live from Dealroom

The Hainan Shuangcheng Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown
Web traffic by country
30 monthly visits
across markets
🇮🇩 Indonesia0%
🇹🇼 Taiwan0%
Top 2 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hainan Shuangcheng Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hainan Shuangcheng Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.